Menu
Recruiting NCT03676868

Biology of Cerebral Arteriovenous Malformations and Prognosis of Cerebral Arteriovenous Malformations

Observational Cerebral Arteriovenous Malformations Ruptured or Unruptured Cerebral Arteriovenous Malformations

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Cerebral Arteriovenous Malformations, Ruptured or Unruptured Cerebral Arteriovenous Malformations. Basic parameters: from 0 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Biology of Cerebral Arteriovenous Malformations : Study of the Link Between Blood Biomarkers and the Haemorrhagic Prognosis of Cerebral Arteriovenous Malformations

Overview

The cerebral arteriovenous malformations correspond to the formation of an entanglement of morphologically abnormal vessels called nidus, which shunt the blood circulation directly from the arterial circulation to the venous circulation. The cerebral arteriovenous malformations are an important cause of hemorrhagic stroke. The hypothesis is that cerebral haemorrhage associated with a cerebral arteriovenous malformations would come from peri-nidal micro-vessels, in connection with infiltration of leucocytes and / or defective maintenance of microvascular integrity by platelets.

Primary outcome measures

  • Associaton between dosage of endothelial marker and the arteriovenous malformation pronostic [Time frame: 6 months]
  • Associaton between dosage of platelet and the arteriovenous malformation pronostic [Time frame: 6 months]
  • Associaton between dosage of neutrophilic and the arteriovenous malformation pronostic [Time frame: 6 months]
  • Associaton between neo-angiogenesis activation markers and the arteriovenous malformation pronostic [Time frame: 6 months]

Eligibility criteria

Inclusion criteria

  • Patient over 18 years old
  • Patient with a cerebral AVM for which an intervention (endovascular treatment or surgery) or only clinical monitoring
  • Express consent to participate in the study

And

  • children
  • Free informed and express consent of both holders of the minor patient's parental authority, or, by way of derogation and only if the other holder of parental authority cannot give his or her consent within a time limit compatible with the methodological requirements specific to the conduct of the research with regard to its purposes, of one of the two holders of parental authority

Exclusion criteria

  • Patient benefiting from a legal protection measure
  • Pregnant or breast feeding woman

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model
Case-only

Study locations

France · 1 center
  • Fondation Ophtalmologique Rotschild — Paris

Identifiers

NCT: NCT03676868 · JDS_2018_6

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗